Developer docs
API playgroundTry for free, no card

Search company profiles

SoniVie

Full company profile

uuid0000gam

Namestring
SoniVie
Legal namestring
SoniVie
Websiteurl
sonivie.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

SoniVie Ltd. was an Israel-based (Rosh Ha'ayin) medical device company founded in 2014, focused exclusively on developing the TIVUS (Therapeutic Intravascular Ultrasound System) for ultrasound-based renal denervation as a treatment for hypertension. The company's core technology uses intravascular ultrasound energy delivered via a catheter to target the renal artery, offering a minimally invasive, non-pharmacological intervention intended to lower blood pressure in patients with hypertension, including those whose condition may be resistant to medication. SoniVie operated in a clinical and regulatory development stage, holding a registered TIVUS trademark and pursuing regulatory approval for its single core product. Its go-to-market motion was anchored on medical conferences, clinical data publication, and physician education through interventional cardiology and hypertension channels, with a future commercial distribution model intended to leverage Boston Scientific's global cardiovascular field sales network following the agreed acquisition.

The company's revenue model was structured around hardware sales of the TIVUS catheter device to hospitals and interventional cardiology providers, though it had not yet generated commercial revenue prior to acquisition. SoniVie was venture-backed, having raised a $60 million Series C in January 2023 led by Andera Partners alongside Omega Funds, Supernova Invest, and TechWald Holding, with prior capital from Accelmed and HeartX. In March 2025, Boston Scientific agreed to acquire SoniVie from Andera Partners for approximately $360 million upfront plus additional payments contingent on regulatory milestones (total deal value up to $600 million), with closing expected in the first half of 2025. Following completion, SoniVie became a wholly-owned subsidiary of Boston Scientific, and its primary customer segment transitioned to hypertension patients served through the acquiring company's established global cardiovascular sales infrastructure.

Short descriptiontext

SoniVie was an Israel-based medical device company developing the TIVUS intravascular ultrasound system for catheter-based renal denervation to treat hypertension, advancing through clinical and regulatory stages before being acquired by Boston Scientific in 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRosh Ha'ayin, Israel
HQ citystring
Rosh Ha'ayin
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
renal denervation, intravascular ultrasound, hypertension treatment, catheter-based therapy, medical device
Industry2 codes
1Interventional Radiology & Image-Guided Therapy Systems
CodeHLAHABAGPrimaryYes
2Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories)
CodeHLAHAKAEPrimaryNo
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Renal Denervation Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

SoniVie develops and commercializes the TIVUS ultrasound-based treatment device for hypertension. Revenue is generated through the sale of medical devices for renal denervation procedures. Prior to acquisition by Boston Scientific, the company was in clinical and regulatory development stages.

prnewswire.co.uk
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SoniVie developed the TIVUS (Therapeutic Intravascular Ultrasound System), a catheter-based ultrasound device designed to perform renal denervation by targeting the renal artery to reduce blood pressure in patients with hypertension. The company was a clinical-stage medical device developer focused on advancing the technology through regulatory milestones prior to its acquisition by Boston Scientific.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

SoniVie was a medical technology company that developed the TIVUS™ Intravascular Ultrasound System, a single core product using ultrasound technology for renal denervation to treat hypertension. The company was acquired by Boston Scientific in 2025 for approximately $360 million upfront plus additional milestone payments.

Product and service1 record
1TIVUS Intravascular Ultrasound System
CategoryRenal Denervation Medical Device
Description

An intravascular ultrasound-based catheter system designed to perform renal denervation by targeting the renal artery to reduce blood pressure in patients with hypertension. Intended for use by interventional cardiologists and hypertension specialists in hospital catheterization laboratories.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Boston Scientific
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-03
Description

Boston Scientific agreed to acquire SoniVie from Andera Partners. The deal involves an upfront payment of approximately $360 million and additional payments upon regulatory milestones, expected to complete in the first half of 2025. This represents Boston Scientific's strategic expansion into ultrasound-based renal denervation for hypertension treatment.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
1ReCor Medical
TypeDirect peer
Description

ReCor Medical developed the Paradise ultrasound renal denervation system, the closest direct competitor to SoniVie's TIVUS. Both companies target the same ultrasound-based RDN mechanism for hypertension and competed head-to-head in the same clinical and regulatory lanes.

2Medtronic
TypeBroad incumbent
Description

Medtronic commercializes the Symplicity Spyral radiofrequency renal denervation system and is the incumbent leader in RDN. It competes with TIVUS in the same resistant-hypertension category and brings significantly larger clinical evidence and commercial reach.

3Ablative Solutions
TypeEmerging player
Description

Ablative Solutions developed the Peregrine System, a catheter-based perivascular renal denervation technology using a chemical ablation approach. It competes with TIVUS in the renal denervation category with a different mechanism but overlapping target indication and customers.

4Boston Scientific
TypeBroad incumbent
Description

Boston Scientific is SoniVie's acquirer and now its operating parent. As a broad cardiovascular medical device incumbent, it competes across hypertension and renal denervation adjacencies and provides the GTM channel SoniVie previously lacked.

5Mercator MedSystems
TypeEmerging player
Description

Mercator MedSystems developed drug-coated balloon technology delivered via micro-infusion catheter, including applications in peripheral vascular disease and hypertension-adjacent indications, making it a relevant emerging player overlapping on intravascular catheter-based interventions.

6Kona Medical
TypeEmerging player
Description

Kona Medical pursued externally delivered focused ultrasound for renal denervation as a non-invasive alternative to catheter-based systems, addressing the same resistant hypertension market with a different (non-invasive) mechanism.

7Verve Medical
TypeEmerging player
Description

Verve Medical develops catheter-based systems targeting autonomic nervous system modulation to treat hypertension and related cardiovascular conditions, putting it in adjacent contention with TIVUS for the renal denervation / resistant hypertension procedure market.

8Cagent Vascular
TypeOthers
Description

Cagent Vascular develops specialty intravascular catheter and serration-based angioplasty technology for vascular disease, sharing with SoniVie the intravascular catheter platform DNA and the same interventional cardiology/hospital procurement channels targeted by TIVUS.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SoniVie

Renal Denervation Devicessonivie.com

SoniVie was an Israel-based medical device company developing the TIVUS intravascular ultrasound system for catheter-based renal denervation to treat hypertension, advancing through clinical and regulatory stages before being acquired by Boston Scientific in 2025.

What SoniVie does

SoniVie Ltd. was an Israel-based (Rosh Ha'ayin) medical device company founded in 2014, focused exclusively on developing the TIVUS (Therapeutic Intravascular Ultrasound System) for ultrasound-based renal denervation as a treatment for hypertension. The company's core technology uses intravascular ultrasound energy delivered via a catheter to target the renal artery, offering a minimally invasive, non-pharmacological intervention intended to lower blood pressure in patients with hypertension, including those whose condition may be resistant to medication. SoniVie operated in a clinical and regulatory development stage, holding a registered TIVUS trademark and pursuing regulatory approval for its single core product. Its go-to-market motion was anchored on medical conferences, clinical data publication, and physician education through interventional cardiology and hypertension channels, with a future commercial distribution model intended to leverage Boston Scientific's global cardiovascular field sales network following the agreed acquisition.

The company's revenue model was structured around hardware sales of the TIVUS catheter device to hospitals and interventional cardiology providers, though it had not yet generated commercial revenue prior to acquisition. SoniVie was venture-backed, having raised a $60 million Series C in January 2023 led by Andera Partners alongside Omega Funds, Supernova Invest, and TechWald Holding, with prior capital from Accelmed and HeartX. In March 2025, Boston Scientific agreed to acquire SoniVie from Andera Partners for approximately $360 million upfront plus additional payments contingent on regulatory milestones (total deal value up to $600 million), with closing expected in the first half of 2025. Following completion, SoniVie became a wholly-owned subsidiary of Boston Scientific, and its primary customer segment transitioned to hypertension patients served through the acquiring company's established global cardiovascular sales infrastructure.

SoniVie firmographics

Firmographics
Name
SoniVie
Legal name
SoniVie
Website
https://sonivie.com
Company type
Private
Founded year
2014
Operating status
Acquired
Headcount range
11–50 employees
Short description
SoniVie was an Israel-based medical device company developing the TIVUS intravascular ultrasound system for catheter-based renal denervation to treat hypertension, advancing through clinical and regulatory stages before being acquired by Boston Scientific in 2025.
Ownership category
akta.pro rank

SoniVie industry classification

Industry
Product category
Renal Denervation Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro primary industry
Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)
akta.pro secondary industry
Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories) (HLAHAKAE)

Keywords

  • Renal denervation
  • Intravascular ultrasound
  • Hypertension treatment
  • Catheter-based therapy
  • Medical device

Where SoniVie is headquartered

Location

Headquarters

HQ city
Rosh Ha'ayin
HQ country
Israel
HQ region
Middle East

Markets served

SoniVie business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: SoniVie develops and commercializes the TIVUS ultrasound-based treatment device for hypertension. Revenue is generated through the sale of medical devices for renal denervation procedures. Prior to acquisition by Boston Scientific, the company was in clinical and regulatory development stages.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

SoniVie product offering

Product offering

Core offering

SoniVie developed the TIVUS (Therapeutic Intravascular Ultrasound System), a catheter-based ultrasound device designed to perform renal denervation by targeting the renal artery to reduce blood pressure in patients with hypertension. The company was a clinical-stage medical device developer focused on advancing the technology through regulatory milestones prior to its acquisition by Boston Scientific.

Product overview

SoniVie was a medical technology company that developed the TIVUS™ Intravascular Ultrasound System, a single core product using ultrasound technology for renal denervation to treat hypertension. The company was acquired by Boston Scientific in 2025 for approximately $360 million upfront plus additional milestone payments.

Differentiator

Problem solved

Functional benefit

Products and services

  • TIVUS Intravascular Ultrasound System An intravascular ultrasound-based catheter system designed to perform renal denervation by targeting the renal artery to reduce blood pressure in patients with hypertension. Intended for use by interventional cardiologists and hypertension specialists in hospital catheterization laboratories.

Companies that use SoniVie

Customer profile

Segments1 record

Ideal customer profiles1 record

SoniVie technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

SoniVie partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Boston ScientificcoreStrategic or Co-development Partner · 3 March 2025Boston Scientific agreed to acquire SoniVie from Andera Partners. The deal involves an upfront payment of approximately $360 million and additional payments upon regulatory milestones, expected to complete in the first half of 2025. This represents Boston Scientific's strategic expansion into ultrasound-based renal denervation for hypertension treatment.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

SoniVie competitors and assessment

Company assessment

Direct peers

  • ReCor Medical: ReCor Medical developed the Paradise ultrasound renal denervation system, the closest direct competitor to SoniVie's TIVUS. Both companies target the same ultrasound-based RDN mechanism for hypertension and competed head-to-head in the same clinical and regulatory lanes.

Broad incumbents

  • Medtronic: Medtronic commercializes the Symplicity Spyral radiofrequency renal denervation system and is the incumbent leader in RDN. It competes with TIVUS in the same resistant-hypertension category and brings significantly larger clinical evidence and commercial reach.
  • Boston Scientific: Boston Scientific is SoniVie's acquirer and now its operating parent. As a broad cardiovascular medical device incumbent, it competes across hypertension and renal denervation adjacencies and provides the GTM channel SoniVie previously lacked.

Emerging players

  • Ablative Solutions: Ablative Solutions developed the Peregrine System, a catheter-based perivascular renal denervation technology using a chemical ablation approach. It competes with TIVUS in the renal denervation category with a different mechanism but overlapping target indication and customers.
  • Mercator MedSystems: Mercator MedSystems developed drug-coated balloon technology delivered via micro-infusion catheter, including applications in peripheral vascular disease and hypertension-adjacent indications, making it a relevant emerging player overlapping on intravascular catheter-based interventions.
  • Kona Medical: Kona Medical pursued externally delivered focused ultrasound for renal denervation as a non-invasive alternative to catheter-based systems, addressing the same resistant hypertension market with a different (non-invasive) mechanism.
  • Verve Medical: Verve Medical develops catheter-based systems targeting autonomic nervous system modulation to treat hypertension and related cardiovascular conditions, putting it in adjacent contention with TIVUS for the renal denervation / resistant hypertension procedure market.

Others

  • Cagent Vascular: Cagent Vascular develops specialty intravascular catheter and serration-based angioplasty technology for vascular disease, sharing with SoniVie the intravascular catheter platform DNA and the same interventional cardiology/hospital procurement channels targeted by TIVUS.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

SoniVie social profiles

Digital presence

SoniVie financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SoniVie leadership team

Management profile

Number of profiles

SoniVie funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SoniVie M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SoniVie

What does SoniVie do?

SoniVie developed the TIVUS (Therapeutic Intravascular Ultrasound System), a catheter-based ultrasound device designed to perform renal denervation by targeting the renal artery to reduce blood pressure in patients with hypertension. The company was a clinical-stage medical device developer focused on advancing the technology through regulatory milestones prior to its acquisition by Boston Scientific.

Is SoniVie a public or private company?

SoniVie is a private company. It is classified as corporate owned and is currently acquired.

When was SoniVie founded?

SoniVie was founded in 2014. It employs 11 to 50 people.

Where is SoniVie based?

SoniVie is headquartered in Rosh Ha'ayin, Israel, in the Middle East region.

How does SoniVie make money?

One revenue line is on record: medical Device Sales.

Who are SoniVie's main competitors?

ReCor Medical is listed as a direct peer. Broad incumbents are Medtronic and Boston Scientific. Emerging players are Ablative Solutions, Mercator MedSystems, Kona Medical and Verve Medical. Cagent Vascular is listed as an others.

Does SoniVie have an API?

No public API is recorded for SoniVie.

What industry is SoniVie in?

SoniVie's product category is Renal Denervation Devices. Its primary akta.pro industry code is HLAHABAG, Interventional Radiology & Image-Guided Therapy Systems, with a secondary code of HLAHAKAE, Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireDeepQure Strengthens Clinical Leadership with Former SoniVie Executive AppointmentDeepQure, a South Korea-based medical technology company, announced the appointment of Jason G. Jones as Global Vice President of Clinical & Regulatory Affairs to accelerate its HyperQure™ renal denervation system development. Jones joins from SoniVie, an Israeli company recently acquired by Boston Scientific for $540 million in March 2025, where he led clinical development strategy and completed enrollment for their Early Feasibility Study. The appointment is expected to strengthen DeepQure's ongoing global clinical trial and advance commercialization of its extravascular RDN technology targeting resistant hypertension.DealformaMedTech, Device, Digital Health, and Wearables M&A and Ventures – Q1 2025Q1 2025 saw a surge in MedTech, device, digital health, and wearables M&A activity, with 24 deals valued at $8.1 billion including $7.6 billion in upfront cash, up from 21 deals totaling $4.2 billion in Q4 2024. Notable acquisitions included Stryker's $4.9 billion buyout of Inari Medical, Zimmer Biomet's $1.2 billion acquisition of Paragon 28, and Boston Scientific's deals for Bolt Medical (up to $900 million) and SoniVie (up to $600 million). Venture funding also accelerated with 63 rounds raising $2.9 billion, more than double the $1.3 billion raised across 49 rounds in Q4 2024, with top raises including BVI Medical's $1 billion round and three $120 million rounds for Supira Medical, FIRE1, and CeQur.The Jerusalem PostBoston Scientific bets on ultrasound tech with SoniVie buyoutBoston Scientific acquires Israeli medtech firm SoniVie for up to $540 million, including an initial payment of $360 million and milestone payments. SoniVie developed a tiny intravascular ultrasound device for nerve denervation to treat medical conditions such as high blood pressure, with recent clinical trial progress toward FDA approval. The deal’s strategic significance lies in Boston Scientific's expansion into ultrasound-based treatments and the advancement of minimally invasive medical technology.CTechBoston Scientific to acquire Israel’s SoniVie for up to $540M in push for hypertensioBoston Scientific is acquiring Israeli medical device company SoniVie in a deal valued at up to $540 million, with the goal of expanding into ultrasound-based hypertension treatments. The acquisition includes an initial cash payment and contingent milestone payments, emphasizing a strategic move into renal denervation therapies. The deal is expected to close in the first half of 2025, subject to regulatory approvals.BenzingaBoston Scientific To Acquire SoniVie For $400 Million, Expanding Hypertension Treatment Portfolio - BostoBoston Scientific Corporation agreed to acquire SoniVie Ltd., a privately held medical device company, for approximately $400 million upfront plus up to $200 million upon achievement of a regulatory milestone, with the transaction expected to close in the first half of 2025. Boston Scientific currently holds approximately 10% equity in SoniVie, making the upfront payment approximately $360 million for the remaining 90%. SoniVie's TIVUS Intravascular Ultrasound System is designed to perform renal denervation for treating hypertension, and the company has initiated the THRIVE global IDE pivotal trial of the device.BostonscientificBoston Scientific announces agreement to acquire SoniVie Ltd.Boston Scientific has entered into a definitive agreement to acquire SoniVie Ltd., the developer of the TIVUS™ Intravascular Ultrasound System, for an upfront payment of approximately $360 million plus up to $180 million in regulatory milestones. The acquisition aims to expand Boston Scientific's interventional cardiology portfolio with an ultrasound-based renal denervation therapy designed to treat hypertension. The transaction is expected to close in the first half of 2025, subject to customary closing conditions.PR NewswireSoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global studySoniVie announced positive 3-month results from its REDUCED-1 pilot study (N=40) showing a -12.0 mmHg average reduction in daytime ambulatory systolic blood pressure with 78.4% responder rate and no device-related adverse events, alongside first-in-human clinical data for its radial access TIVUS catheter. The company also received FDA IDE approval for the THRIVE pivotal study, an international multicenter randomized sham-controlled trial designed to evaluate the TIVUS System in hypertensive subjects, with first patient enrollment expected in Q4 2024 across US, Europe, and Israel sites.BufferAndera Partners backs $60 million series C for hypertension medtech SoniVieSoniVie has closed a $60 million Series C funding round led by Andera Partners to advance its clinical and regulatory pipeline for hypertension treatment. The company's TIVUS device utilizes ultrasound to ablate nerves in the renal artery, with future iterations potentially targeting lung arteries for chronic obstructive pulmonary disease. As part of the deal, SoniVie is adding two independent board members, including a representative from Johnson & Johnson Innovation.Next FinanceAndera Partners réalise un investissement dans SoniVie, une société medtech développant un dispositif prometteur dans le traitement de l’hypertensionSoniVie announced the closing of a $60 million Series C funding round led by Andera Partners, with participation from Supernova Invest, Omega Funds, and TechWald. The capital will support the clinical and regulatory development of SoniVie's TIVUS™ ultrasound technology for hypertension treatment, alongside the creation of a new French subsidiary for clinical operations. Two independent experts were also appointed to the board to strengthen governance in this area.PR NewswireSoniVie Raises $60m in Round C Financing, and Appoints New Board MembersSoniVie Ltd., a medical device company based in Tel Aviv, Israel, completed a $60 million Series C financing round led by Andera Partners with participation from Supernova Invest, Omega Funds, and TechWald. The proceeds will support clinical and regulatory milestones for TIVUS™, an ultrasound-based renal artery denervation system for treating hypertension. The company also appointed Raymond W. Cohen and Zeev Zehavi as independent directors to its board.